<DOC>
	<DOCNO>NCT02018757</DOCNO>
	<brief_summary>The purpose study determine whether transarterial chemoembolization contain arsenic trioxide safe effective treatment intermediate-stage hepatocellular carcinoma .</brief_summary>
	<brief_title>Safety Efficacy Arsenic Trioxide Contained TACE Treatment HCC</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Arsenic trioxide</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<criteria>accordance primary hepatocellular carcinoma diagnosis standard：cytohistology standard noninvasive standard.1）+2）a 1）+2）b+3）of follow noninvasive diagnosis criterion : ( 1 ) patient HBV HCV relate liver cirrhosis . ( 2 ) radiological lesion ( ) liver arterial hypervascularity venous delayed phase washout : a.one kind image technology diagnosis lesion &gt; 2cm ; b.two kind image technology obtains consistent conclusion lesion diameter 12 cm . ( 3 ) serum AFP level ≥400 ug/L last 1 month ≥200 ug/L last 2 month , disease may cause AFP level increase exclude , pregnancy , genital embryonic tumor active hepatitis . age 18 75 year , male female life expectancy 12 week Barcelona Clinic Liver Cancer ( BCLC ) stage B laboratory test : ( 1 ) leukocyte &gt; 3*19^9/L ; ( 2 ) hemoglobin≥8.5g/dl ; ( 3 ) platelet count ≥50*10^9/L , ( 4 ) ALT AST less three time normal limit ; ( 5 ) albumin ≥ 3.0 g/dl ; ( 6 ) total bilirubin acuity 3 mg/dl ; ( 7 ) prothrombin time international standardization ratio ( PT INR ) &lt; = 2.3 prothrombin time ( PT ) normal compare 3 second ; ( 8 ) serum creatinine less 1.5 time normal upper limit patient sign informed consent concomitant malignancy distinct HCC currently previously allergic subject agent ( arsenic ) agent relate trial BCLC stage 0 , A , C D HCC account 70 % liver size liver function ChildPugh score C ECOG score 1 high severe heart disease , congestive heart failure cardiac function New York Heart Association ( NYHA ) functional class II severe , active coronary disease ( except myocardial infarction 6 month ) cardiac arrhythmia need medical management ( except controllable βblockers、calcium channel blocker digoxin ) uncontrollable hypertension ( diastolic blood pressure control 90 mmHg even antihypertension treatment antihypertensive drug ) . active severe infection ( grade 2 high accord NCICTCAE version 4.0 ) active tuberculosis pulmonary tuberculosis exclude CNS malignancy , include intracranial metastasis gastrointestinal bleed clinical finding previous 30 day chronic renal failure pregnancy breastfeed unstable condition circumstance possibly jeopardise safety compliance subject .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Carcinoma , Hepatocellular</keyword>
	<keyword>primary liver cancer</keyword>
	<keyword>primary hepatocellular carcinoma</keyword>
	<keyword>transarterial chemoembolization</keyword>
	<keyword>Chemoembolization , Therapeutic</keyword>
	<keyword>arsenic trioxide</keyword>
	<keyword>arsenous anhydride</keyword>
	<keyword>diarsenic trioxide</keyword>
	<keyword>randomize control trial</keyword>
	<keyword>multicenter study</keyword>
	<keyword>HCC</keyword>
	<keyword>TACE</keyword>
</DOC>